Healthcare of Ontario Pension Plan Trust Fund Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Healthcare of Ontario Pension Plan Trust Fund bought a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 34,207 shares of the company’s stock, valued at approximately $341,000.

A number of other hedge funds have also added to or reduced their stakes in RXRX. Benjamin F. Edwards & Company Inc. bought a new stake in Recursion Pharmaceuticals in the first quarter worth approximately $26,000. National Bank of Canada FI increased its holdings in Recursion Pharmaceuticals by 90.9% in the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after purchasing an additional 1,500 shares in the last quarter. First Horizon Advisors Inc. bought a new stake in Recursion Pharmaceuticals in the fourth quarter worth approximately $47,000. Daiwa Securities Group Inc. increased its holdings in Recursion Pharmaceuticals by 1,508.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 11,759 shares of the company’s stock worth $116,000 after purchasing an additional 11,028 shares in the last quarter. Finally, Oxinas Partners Wealth Management LLC bought a new stake in Recursion Pharmaceuticals in the first quarter worth approximately $122,000. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $8.05 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.97 and a 52 week high of $15.74. The business has a 50 day moving average price of $8.52 and a 200-day moving average price of $9.63.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The firm had revenue of $13.80 million during the quarter, compared to the consensus estimate of $11.10 million. During the same quarter in the previous year, the company posted ($0.34) earnings per share. The company’s quarterly revenue was up 14.0% on a year-over-year basis. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Insider Buying and Selling

In related news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $7.95, for a total transaction of $91,003.65. Following the completion of the sale, the director now owns 7,218,414 shares in the company, valued at $57,386,391.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $7.95, for a total transaction of $91,003.65. Following the completion of the sale, the director now owns 7,218,414 shares in the company, valued at $57,386,391.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher Gibson sold 50,000 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total value of $386,500.00. Following the sale, the chief executive officer now owns 863,524 shares of the company’s stock, valued at approximately $6,675,040.52. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 257,682 shares of company stock worth $2,083,123. 15.75% of the stock is owned by corporate insiders.

Analyst Ratings Changes

RXRX has been the subject of several recent research reports. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Needham & Company LLC restated a “buy” rating and set a $17.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday, June 25th.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.